Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Br J Haematol. 2016 Jul 19;175(3):496–504. doi: 10.1111/bjh.14260

Figure 3. Rates of (A) acute myeloid leukaemia (AML) relapse, (B) non-relapse mortality (NRM) and (C) chronic graft-versus-host disease (GVHD) among sorafenib patients (dashed line) and controls (solid line).

Figure 3

Control patients had a significantly higher cumulative incidence of relapse (A; p=0.0077). There was no significant difference in NRM (B) or chronic GVHD rates (C) between sorafenib and control patients.